ivosidenib
servier
['ivosidenib', 'mds']
congress #eha2023 | courtney dinardo presents phase i substudy results of oral ivosidenib in pts with mutant idh1 relapsed/refractory #mds. cr+pr rate was 38.9% &amp; orr was 83.3%. safety profile was acceptable; traes occurred in 42.1% pts.
#mdssm 
Lifting levels of knowledge in myelodysplastic syndromes (#MDS). A global online platform providing latest treatment options and medical information. #mdssm